Such remote reactivations could result in increased levels of virus-specific IgM, IgG or DNA in tissues without relevance to MS pathology and could contribute HHV-6A signal in sampled tissue (e.g. serum and PBMCs) in the absence of MS lesion-relevant reactivation. This evidence concerns the gene CD40LG and myeloid sarcoma.